Compared with current anti-OX40 field leader, PF-04518600, BAT6026 demonstrated superior activities on binding to OX40, blocking binding of OX40L to OX40, activation of T cells and SEB-pretreated PBMCs, as well as tumor inhibition in MC38 tumor model of OX40-humanized mice. The gene discussed is TNFRSF4; the disease is neoplasm.